Critical Contrast: Solid Biosciences (NASDAQ:SLDB) vs. BIONDVAX PHARMA/S (NASDAQ:BVXV)

Solid Biosciences (NASDAQ:SLDB) and BIONDVAX PHARMA/S (NASDAQ:BVXV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Valuation & Earnings

This table compares Solid Biosciences and BIONDVAX PHARMA/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$74.80 million ($2.25) -2.32
BIONDVAX PHARMA/S N/A N/A -$23.41 million ($3.60) -1.70

Solid Biosciences is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.


This table compares Solid Biosciences and BIONDVAX PHARMA/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A -67.34% -60.88%
BIONDVAX PHARMA/S N/A -773.59% -82.26%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Solid Biosciences and BIONDVAX PHARMA/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 2 5 1 0 1.88

Solid Biosciences presently has a consensus price target of $21.75, indicating a potential upside of 317.47%. Given Solid Biosciences’ higher possible upside, analysts plainly believe Solid Biosciences is more favorable than BIONDVAX PHARMA/S.

Insider & Institutional Ownership

59.4% of Solid Biosciences shares are owned by institutional investors. Comparatively, 6.6% of BIONDVAX PHARMA/S shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by company insiders. Comparatively, 6.0% of BIONDVAX PHARMA/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Solid Biosciences has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.


Solid Biosciences beats BIONDVAX PHARMA/S on 8 of the 10 factors compared between the two stocks.

Solid Biosciences Company Profile

Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with's FREE daily email newsletter.